Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention.

Richard B LiptonPeter J GoadsbyDavid W DodickJames S McGinleyCarrie R HoutsR J WirthSteve KymesAnders EttrupOle ØsterbergRoger CadyAnne Luise Haulund VollesenDawn C Buse

Published in: Headache (2022)

Improvement in PI-MBS at week 12 was associated with improvement in other patient-reported outcome measures, and PI-MBS may be an important patient-centered measure of treatment benefits in patients with chronic migraine.

Keyphrases

patient reported
case report
randomized controlled trial
machine learning
artificial intelligence